Comparison of Clinical Efficacy of Dual-Targeted Neoadjuvant Drugs Combined with Different Chemotherapy Regimens in the Treatment of HER-2 Positive Breast Cancer
Objective To investigate the clinical efficacy of dual-targeted neoadjuvant drugs combined with different chemotherapy regimens in the treatment of human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods A total of 110 patients with HER-2 positive breast cancer admitted to the First People's Hospital of Liangshan Yi Autonomous Prefecture from January 2019 to December 2022 were selected and divided into the TcbHP group and the AC-THP group based on different treatment methods,with 55 cases in each group.The patients in the TcbHP group were treated with trastuzumab and pertuzumab combined with taxanes(docetaxel or paclitaxel)and carboplatin for six cycles,with 21 d as a cycle.The patients in the AC-THP group were treated with trastuzumab and pertuzumab combined with anthracyclines(pirarubicin or epirubicin)and cyclophosphamide for eight cycles(trastuzumab and pertuzumab for four cycles,other drugs for four cycles),with 21 d as a cycle.Results The pathological complete remission rate in the TcbHP group was 61.80%,which was slightly higher than 50.90%in the AC-THP group(P>0.05).After treatment,the degree of nausea,vomiting,diarrhea,cardiotoxicity and hand-foot syndrome in the TcbHP group was significantly lower than that in the AC-THP group(P<0.05);the various tumor markers[carbohydrate antigens(CA19-9,CA125,CA153),carcinoembryonic antigen(CEA)]levels were significantly lower than those in the AC-THP group(P<0.05);the left ventricular ejection fraction(LVEF),serum cardiac troponin I(cTnI),creatine kinase isoenzyme-MB(CK-MB),and amino-terminal pro B-type natriuretic peptide(NT-proBNP)levels showed no significant changes(P>0.05),and those were significantly better than those in the AC-THP group(P<0.05).Conclusion The efficacy of TcbHP regimen in the treatment of HER-2 positive breast cancer is similar to that of AC-THP regimen,but the former is more effective in decreasing the tumor marker levels and has lower risk of cardiotoxicity.
国家科技期刊平台
NSTL
万方数据
维普
